Scientific Studies and Articles Relevant to Canine Hepatocellular Carcinoma and Its Management

A curated resource for exploring research on canine hepatocellular carcinoma, related therapies, and integrative oncology approaches.

This page compiles scientific studies and articles relevant to canine hepatocellular carcinoma (HCC) and its management, including veterinary research, supportive medications, and nutritional supplements. While the primary focus is on HCC in dogs, selected research from other cancer types or species is included for its potential comparative or translational insight into supportive care and treatment strategies.

Canine HCC Medications Supplements Non-Canine Studies

Canine Hepatocellular Carcinoma

This section features studies and articles specifically focused on hepatocellular carcinoma (HCC) in dogs. Topics cover diagnosis, imaging, surgical outcomes, chemotherapy and targeted therapies, and prognostic indicators.

survivalcancercanineliverhepatocellular carcinoma

Factors Associated with Survival in Dogs with a Histopathological Diagnosis of Hepatocellular Carcinoma: 94 Cases (2007–2018)

by James Moyer, Daniel J Lopez, Cheryl E Balkman, and Julia P Sumner

This retrospective study of 94 dogs with hepatocellular carcinoma evaluated survival and prognostic factors after tumor resection or biopsy. Median survival time was 707 days. Negative prognostic factors included central (quadrate lobe) tumor location, higher ASA score, and elevated BUN, potassium, or GGT. Resection of the right medial lobe was associated with an increased risk of perioperative mortality, and surgical resection did not significantly improve long-term survival compared with biopsy alone. Overall, dogs with HCC generally had a favorable long-term prognosis.

Read article

survivalcancercanineliverhepatocellular carcinoma

Massive Hepatocellular Carcinoma in Dogs: 48 Cases (1992-2002)

by Julius M Liptak, William S Dernell, Eric Monnet, Barbara E Powers, Annette M Bachand, Juanita G Kenney, and Stephen J Withrow

This retrospective study of 48 dogs with the massive subtype of hepatocellular carcinoma (HCC) compared outcomes in dogs treated with lobectomy versus conservative management. Dogs undergoing surgical removal had a median survival time of > 1,460 days and no local recurrence, with low rates of metastasis, while non‑surgically managed dogs had a median survival of 270 days. Elevated ALT and AST activities and right‑sided liver lobe location were identified as negative prognostic factors. The study found that dogs with massive HCC are amenable to surgical resection and may achieve prolonged survival through surgery.

Read article

sorafenibmetronomic chemotherapyclinical trialhepatocellular carcinoma

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs

by Laura Marconato, Silvia Sabattini, Giorgia Marisi, Federica Rossi, Vito Ferdinando Leone, and Andrea Casadei-Gardini

This article reports on a clinical trial that compared sorafenib to metronomic chemotherapy in dogs with advanced, unresectable hepatocellular carcinoma, with findings suggesting that sorafenib may be a promising treatment option.

Read article

retrospective studydiagnosishepatocellular carcinoma

Retrospective Study of Cytologic Features of Well-Differentiated Hepatocellular Carcinoma in Dogs

by Carlo Masserdotti and Michele Drigo

This article details a retrospective study aimed at identifying cell-level characteristics of well-differentiated hepatocellular carcinoma in dogs, with the goal of developing reliable diagnostic criteria for cases where typical signs of cancer in liver cells are absent.

Read article

hepatocellular massestranscatheter arterial embolizationretroactive study

Therapeutic Response and Prognostic Factors of 14 Dogs Undergoing Transcatheter Arterial Embolization for Hepatocellular Masses: A Retrospective Study

by Yuta Kawamura, Hiroki Itou, Akitomo Kida, Hiroki Sunakawa, Moe Suzuki, and Kenji Kawamura

This retrospective study investigated the therapeutic response and prognostic factors in dogs treated with transcatheter arterial embolization (TAE) for primary hepatocellular masses, evaluating overall survival and identifying potential outcome predictors.

Read article

hepatocellular carcinomarecurrancesurvivalcase-control study

Risk Factors and Outcome in Dogs with Recurrent Massive Hepatocellular Carcinoma: A Veterinary Society of Surgical Oncology Case–Control Study

by Janis M Lapsley, Vincent Wavreille, Sabrina Barry, Josephine A Dornbusch, Carolyn Chen, Haley Leeper, Judith Bertran, Diane Scavelli, Julius M Liptak, Chris Wood, Shelly Shamir, Claire Rosenbaum, Vincenzo Montinaro, Brandan Wustefeld‐Janssens, Allyson Sterman, Colin Chik, Ameet Singh, Josh Collins, and Laura E Selmic

This case–control study examined time to recurrence, potential risk factors, and outcomes in dogs with massive hepatocellular carcinoma (HCC). Although no clear risk factors were identified, elevated liver values may support disease surveillance. Routine post-operative monitoring was associated with earlier recurrence detection, and treatment at recurrence showed a trend toward improved survival, though not significantly different from no treatment at recurrence.

Read article

Medications for Hepatocellular Carcinoma or Related Conditions

This section features content on medications and pharmaceuticals used either to directly treat canine HCC or to manage related conditions such as liver dysfunction, fibrosis, inflammation, or systemic effects. This includes medications like telmisartan, toceranib, ursodiol, and others with potential roles in supportive or adjunctive therapy.

telmisartanproteinuriacanine

Treatment of Proteinuria in Dogs with Telmisartan: A Retrospective Study

by Julie Lecavalier, Lyanne Fifle, and Romain Javard

This retrospective study describes the use of telmisartan for proteinuria in 44 dogs, either alone or with other therapies. Most dogs experienced a decrease in proteinuria, and telmisartan was generally well tolerated. In dogs treated with telmisartan alone, many experienced a favorable response as observed at scheduled follow-up intervals. While improvement cannot be attributed solely to telmisartan for all dogs, the findings support further research.

Read article

telmisartanproteinuriacanine

Telmisartan Treatment of Refractory Proteinuria in a Dog

by AC Bugbee, AE Coleman, A Wang, AD Woolcock, and SA Brown

This single-case report describes a 6‑year‑old beagle with long‑standing, refractory proteinuria despite blood pressure control with amlodipine and treatment with ACE inhibitor benazepril. After initiating the angiotensin II receptor blocker telmisartan, the dog’s proteinuria markedly improved over several weeks. The dog was able to be weaned off additional antiproteinuria therapies, and no adverse reactions were observed, supporting further investigation of ARB therapy in canine proteinuria.

Read article

Supplements in Cancer Care

This section includes research on dietary supplements and nutraceuticals used in canine cancer support. They are included for their potential relevance to integrative or supportive care in canine HCC.

canine cancerhemangiosarcoma

Compound Derived From a Mushroom Lengthens Survival Time in Dogs With Cancer, Penn Vet Study Finds

by Katherine Unger Baillie

This 2012 article discusses results of a Penn Vet study that examined whether a compound from the Coriolus versicolor mushroom could extend survival time in dogs with hemangiosarcoma, an aggressive cancer, and points to the compound’s potential as an alternative or complementary treatment to chemotherapy.

Read article

hemangiosarcomacanine cancer

Single Agent Polysaccharopeptide Delays Metastases and Improves Survival in Naturally Occurring Hemangiosarcoma

by Dorothy Cimino Brown and Jennifer Reetz

This scientific article highlights research from a pilot study in which polysaccharopeptide was found to delay metastasis and improve survival in dogs with hemangiosarcoma, offering promising potential as a treatment option for canine cancer.

Read article

Relevant Non-Canine Studies and Articles for Comparative Insight

Although this page focuses on canine HCC, research from other species can offer valuable therapeutic insights. This section highlights selected non-canine studies on pharmaceuticals and medications, supplements, and treatment strategies that may inform veterinary approaches or inspire future research in dogs.

liver cancerhepatocellular carcinomamicrobiomediagnostic biomarkernovel therapies

The Gut Microbiome and Hepatocellular Carcinoma: Implications for Early Diagnostic Biomarkers and Novel Therapies

by Yongbo Kang, Yue Cai, and Ying Yang

This review explores how changes in the gut microbiome may contribute to hepatocellular carcinoma (HCC) and how gut microbiota may serve as an early diagnostic biomarker. Based on evidence from mouse and rat models and early human studies, it also discusses how manipulating the microbiome could be a potential strategy to prevent or treat HCC, using approaches with a generally high safety profile and low risk of severe adverse effects, such as probiotics, prebiotics, synbiotics, fecal microbiota transplantation (FMT), and antibiotics. Although these approaches appear promising, the authors note that further research is needed to develop diagnostic, prognostic, and therapeutic strategies.

Read article